Hormonal Changes and GI Function in Menopausal Women with FGIDs
Overview
Menopausal women experience a high prevalence of functional gastrointestinal disorders (FGIDs) linked to fluctuations in sex hormones, particularly estrogen and progesterone. These hormones regulate GI function through direct receptor-mediated effects and indirect pathways involving the gut microbiota, immune system, and central nervous system, influencing symptom severity and response to hormone replacement therapy.
Background
Functional gastrointestinal disorders (FGIDs) are chronic conditions characterized by recurrent GI symptoms without structural abnormalities, with a higher incidence in menopausal women. The decline in estrogen and progesterone during menopause reduces their protective effects on GI function, contributing to disorders such as irritable bowel syndrome and functional dyspepsia. Sex hormones modulate GI motility, visceral sensitivity, immune activation, and gut–brain axis interactions. Hormone replacement therapy (HRT) shows variable effects on GI symptoms, highlighting the complexity of hormonal regulation in this population.
Data Highlights
Studies indicate menopausal women are 2.9 times more likely to experience abnormal GI symptoms including functional heartburn, reflux hypersensitivity, and irregular GI motility. Clinical data show that estrogen supplementation can promote gastric emptying, while HRT may increase gastroparesis risk. Experimental models demonstrate 17 β-estradiol restores gastric emptying by improving Nrf2 and nNOS functions in ovariectomized mice with diabetes.
Key Findings
Sex hormones exert direct effects on GI function via receptors in the GI tract, CNS, pancreatic islets, and thyroid tissue.
Estrogen and progesterone decline post-menopause correlates with increased FGIDs symptom severity.
Hormonal fluctuations influence gut microbiota composition, immune responses, and central nervous system regulation of GI function.
HRT shows mixed clinical effects: increased gastroparesis risk but estrogen alone may improve gastric motility.
FGIDs in menopausal women are linked to climacteric syndrome, depression, anxiety, and sleep disorders through complex feedback loops.
Understanding molecular mechanisms of sex hormone regulation on GI function can guide novel therapeutic strategies for FGIDs in menopausal women.
Clinical Implications
Clinicians should consider the multifactorial role of sex hormones when evaluating and managing FGIDs in menopausal women. Hormone replacement therapy requires careful assessment due to its variable effects on GI symptoms. Targeting hormonal pathways and gut microbiota interactions may offer new avenues for personalized treatment of menopausal FGIDs.
Conclusion
Sex hormone fluctuations during menopause significantly impact gastrointestinal function through complex direct and indirect mechanisms, contributing to the high prevalence of FGIDs in this population. Further research into hormonal regulation and therapeutic modulation may improve management strategies for menopausal women with FGIDs.
References
Author/Source/Year -- Hormonal Changes and Gastrointestinal Function in Menopausal Women with Functional Disorders
